News
Cosmos Holdings, Inc. Completes $500,000 Debt-to-Equity Conversion at $7.50 Per Share
CHICAGO, May 31, 2019 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (“Cosmos” or the “Company”) (OTCQB: COSM), an international pharmaceutical company, announced today it agreed to issue 66,667 shares of common stock to Grigorios Siokas, the Company’s CEO, in exchange for the repayment of $500,000 of loans due to Mr. Siokas. The effective conversion rate is $7.50 per share, 117% higher than the $3.45 closing share price of Cosmos on May 29, 2019. Following the conversion of the loans, Cosmos will ...
Cosmos Holdings, Inc. Announces Year End 2018 Financial Results
CHICAGO, April 23, 2019 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. ("the Company") (OTCQB: COSM), an international pharmaceutical company, announced its full-year 2018 financial results for the year ended December 31, 2018. 2018 Highlights: - Revenue improved 23.6% to $37 million from $30 million in 2017 - Gross profit increase 23.1% to $2.4 million from $1.96 million in 2017 - Operating expenses decreased by 46.7% year over year. - Repaid the remaining balance of its convertible notes, totaling $5.5 million. - Completed the acquisition of Cosmofarm Ltd., ...
Cosmos Holdings, Inc. Adds to Its Advisory Board
CHICAGO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. ("the Company") (OTCQB: COSM), an international pharmaceutical company, announced that it has added executive Vassos Efthymiadis to its advisory board. Mr. Efthymiadis is the Managing Director of K&N Efthymiadis S.A. and Vice President of the Redestos Agrotechnology Group, both companies are leaders in agribusiness in Greece. Mr. Efthymiadis is also President of the Hellenic Crop Protection Association, Board Member of the Hellenic Association of Chemical Industries, and Advisory ...
Cosmos Holdings, Inc. Pays Off All Convertible Debt
CHICAGO, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. (OTCQB: COSM), an international pharmaceutical company, announced today that it paid off the remaining balance of its convertible notes. The aggregate initial principal amounts of the notes totaled $5,583,333. Cosmos Holdings CEO Gregory Siokas commented, “We are excited to announce the repayment of all our convertible debt. With the acquisition of Cosmofarm that closed in December of last year, and this note repayment, we believe are well-positioned for growth ...
Cosmos Holdings, Inc. Adds Distinguished Portfolio Manager With Mid-Cap & Large-Cap Value Expertise to Its Advisory Board
CHICAGO, Jan. 11, 2019 (GLOBE NEWSWIRE) -- Cosmos Holdings, Inc. ("the Company") (OTCQB: COSM), an international pharmaceutical company, announced that it has added Tom Kolefas to its Advisory Board. Kolefas brings more than 25 years of Wall Street experience on the buyside - managing both mutual fund and institutional equities at TIAA Investments, Jennison Associates, Loomis Sayles, Mackay-Shields and Bank of New York; as well as industry experience as a chemical engineer and corporate development officer at Engelhard/BASF. The Company ...
Photo
David E. Gutierrez
Head of PR, IR
and Corporate Development

Join our mailing list to stay up to date.

Cosmos-logo